Patent ID: 8808714
Filing Date: 2014-08-19
Classification: A61K

Abstract:
1. A pharmaceutical composition, comprising: (a) a core containing one or more pharmaceutically active ingredients selected from one or more of psychotropics, anti-depressants, anti-manics, antiparkinsonian substances, agents for the treatment of hyperactivity or attention deficit hyperactivity disorders, stimulants, sedatives, anticonvulsants, and antispasmodics, and (b) a coating layer surrounding the core, said coating layer comprising a combination of three or more enteric coating materials selected from the group consisting of cellulose acetate phthalate; hydroxypropyl methylcellulose phthalate; polyvinyl acetate phthalate; hydroxypropyl methylcellulose acetate succinate; cellulose acetate trimellitate; copolymer of methylvinyl ether and maleic anhydride; zein; methacrylic acid copolymers; acrylate copolymers; hydroxypropyl methylcellulose phthalate/poly(methacrylic acid-co-methyl methacrylate 1:1/poly(methacrylic acid-co-methyl methacrylate) 1:2; hydroxypropyl methylcellulose phthalate/cellulose acetate phthalate/poly(methacrylic acid-co-methyl methacrylate) 1:2; hydroxypropyl methylcellulose phthalate/cellulose acetate phthalate/poly(methacrylic acid-co-methyl methacrylate 1:1/poly(methacrylic acid-co-methyl methacrylate) 1:2; polyvinyl acetate phthalate/cellulose acetate trimellitate/zein/poly(methacrylic acid-co-methyl methacrylate) 1:2, at least two of which enteric coating materials dissolve at a different pH in the small intestine, wherein the active ingredient(s) has a release profile that is pH-dependent, wherein the release profile is at first sustained while the composition is in a part of the small intestine of a first pH and then accelerated when the composition is in a part of the small intestine of a second pH, and wherein said first pH is lower than said second pH, and wherein more than 70% of the active ingredient(s) is dissolved prior to entering the large intestine.